I am an experienced statistician and executive. As Chief Scientific Officer at Cytel, I led the company through two sales to private equity in 2017 and in 2021.
Over the course of 15 years, I have led the development of Cytel’s software and strategic consulting offerings. In my current role as CSO, I have oversight of the corporate-level scientific agenda. This includes research portfolios in complex and innovative clinical trial designs, Bayesian methods, platform trials and master protocols, and advanced uses of real-world evidence to strengthen regulatory submissions.
My research interests include causal inference, adaptive trial design, financial and clinical strategy, statistical computing and regulatory affairs.
I also set the vision and guides the development of Cytel’s software products, ensuring that Cytel’s prolific scientific innovations are rapidly made available to clients. This includes Solara TM, a trial strategy platform for teams to confidently align on the right design, as well as industry leading statistical design packages East and Compass, and exact statistics applications StatXact and LogXact.
I have published in numerous statistical journals. I earned a Ph.D. in Biostatistics from Harvard University, an M.P.H. from Columbia University, and a B.A. in Molecular and Cellular Biology also from Harvard.